Sign Out
Sofosbuvir is a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor indicated for the treatment of chronic hepatitis C (CHC) infection as a combination with Ribavirin or in combination with Pegylated interferon and Ribavirin.
Sofosbuvir efficacy has been established in patients with HCV genotype 1 (naive), genotype 2 or 3 infection including those with hepatocellular carcinoma meeting Milan criteria (awaiting liver transplantation) and those with HCV/HIV-1 co-infection.
The following points should be considered when initiating treatment with Sofosbuvir: Monotherapy of Sofosbuvir is not recommended for treatment of CHC; Treatment regimen and duration are dependent on both viral genotype and patient population; Treatment response varies based on baseline host and viral factors.
